Pills. Needles. Dyve. Dyve Bioscience’s mission is to legitimize the skin as a viable 3rd route of drug delivery, providing breakthrough topical therapy where oral or injectable dosage forms are unsuitable due to safety or pharmacokinetic issues. Our paradigm-shifting transdermal platform allows us to formulate a broad range of molecules without compromising pharmacokinetics. For more information, please visit www.dyvebio.com Corporate Contact Jim McGee Dyve Biosciences, Inc. 805-857-6449 jim.mcgee@dyvebio.com Investor Contact Corey Davis LifeSci Advisors, LLC 212-915-2577 cdavis@lifesciadvisors.com
Location: United States, California, Camarillo
Employees: 11-50
Founded date: 2014
Investors 1
| Date | Name | Website |
| - | NaHCO3 | nahco3.com |
Mentions in press and media 1
| Date | Title | Description |
| 25.06.2021 | Roth Capital Partners to Host a Virtual Healthcare Private Company Forum on June 28, 2021 | NEWPORT BEACH, Calif., June 25, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Roth Capital Partners (“Roth”), www.roth.com, is set to virtually present the Roth Virtual Healthcare Private Company Forum on June 28th, 2021. This event will con... |